Drugs / tozuleristide
tozuleristide
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT02464332 | Sep 2015 → May 2016 | soft tissue sarcoma | Blaze Bioscience Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02496065 | Jul 2015 → Dec 2016 | breast cancer | Blaze Bioscience Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02462629 | Jun 2015 → Jul 2018 | central nervous system neoplasm | Blaze Bioscience Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02234297 | Oct 2014 → Feb 2016 | glioma | Blaze Bioscience Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02097875 | Dec 2013 → Mar 2015 | skin neoplasm | Blaze Bioscience Australia Pty Ltd | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05316688 | Apr 2024 → Sep 2025 | oral cavity squamous cell carcinoma | University of Washington | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04743310 | Sep 2021 → Mar 2025 | central nervous system neoplasm | John Yu | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT03579602 | Nov 2018 → Apr 2022 | central nervous system neoplasm | Blaze Bioscience Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| — | NCT04343274 Background | — | — | Blaze Bioscience Inc. | No longer available | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tozuleristide | “BLZ-100 (tozuleristide) is an intraoperative fluorescent imaging agent that selectively detects malignant tissue and can be used in real time to guide tumor resection.” PMID 34401600 ↗ Aug 2021 |
| Known as | BLZ-100 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02496065 ↗ |
| Known as | Tozuleristida | ChEMBL registry synonym — accepted as the source's own label CHEMBL3990023 ↗ |
| Modality | Diagnostic / imaging agent | “BLZ-100 (tozuleristide) is an intraoperative fluorescent imaging agent” PMID 34401600 ↗ Aug 2021 |
| Route | Intravenous | “BLZ-100 was administered intravenously to 21 adult patients 2 days before excising known or suspected skin cancers.” PMID 34401600 ↗ Aug 2021 |